Retraction: MicroRNA-218 inhibits proliferation and invasion in ovarian cancer by targeting Runx2

Na Li; Lufei Wang; Guangyun Tan; Zhiheng Guo; Lei Liu; Ming Yang; Jin He

doi:10.18632/oncotarget.28253

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Retraction:

Retraction: MicroRNA-218 inhibits proliferation and invasion in ovarian cancer by targeting Runx2

PDF | How to cite

Oncotarget. 2022; 13:863-863. https://doi.org/10.18632/oncotarget.28253

Metrics: PDF 673 views | ?

Na Li¹, Lufei Wang², Guangyun Tan³, Zhiheng Guo¹, Lei Liu¹, Ming Yang^4,* and Jin He^1,*

¹Department of Gynecology and Obstetrics, The First Hospital of Jilin University, Changchun, Jilin 130021, PR China
²Department of Ophthalmology, The Second Hospital of Jilin University, Changchun, Jilin 130022, PR China
³Department of Immunology, Institute of Translational Medicine of The First Hospital of Jilin University, Changchun, Jilin 130021, PR China
⁴Department of Breast Surgery, The First Hospital of Jilin University, Changchun, Jilin 130021, PR China
^*These authors have contributed equally to this work

Published: July 02, 2022

Copyright: © 2022 Li et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been retracted: Oncotarget has completed its investigation of this paper. We found that Figures 2C, 2E, 5C, 5D, 6E, and Table 1 contain similarities with data appearing in other articles by different authors. The data had already been published elsewhere, or were already under consideration for publication prior to submission to Oncotarget. During our long period of communication with the authors, we received a request from corresponding author Jin He to retract the paper. As of this writing, Oncotarget has not received signed documentation from all authors acknowledging the retraction. Oncotarget has also notified the affiliated institution regarding this retraction.

Original article: Oncotarget. 2017; 8:91530–91541. DOI: https://doi.org/10.18632/oncotarget.21069.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28253

Publication Alerts

Retraction:

Retraction: MicroRNA-218 inhibits proliferation and invasion in ovarian cancer by targeting Runx2